Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$40.93 USD

40.93
2,161,941

-0.09 (-0.22%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $40.94 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio

by Zacks Equity Research

Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.

Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Comfort Systems USA and Boeing are part of the Zacks Bull and Bear of the Day article.

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

by Indrajit Bandyopadhyay

Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

Reasons to Hold Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.

Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy

by Zacks Equity Research

Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.

Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand

by Zacks Equity Research

Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.

Baxter (BAX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 2.33% and 2.28%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Countdown to Baxter (BAX) Q4 Earnings: Wall Street Forecasts for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Baxter (BAX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Reasons to Retain Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business

by Zacks Equity Research

Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.

Shaun Pruitt headshot

3 Medical Products Stocks to Consider as Earnings Approach

by Shaun Pruitt

These top-rated Zacks Medical sector stocks are very attractive ahead of their quarterly reports on Thursday, November 2 with now looking like an ideal time to invest.

What's in Store for Cardinal Health (CAH) in Q1 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) first-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.

Indrajit Bandyopadhyay headshot

Medical Product Stocks' Q3 Earnings Due on Nov 1: SYK & More

by Indrajit Bandyopadhyay

Third-quarter results of Medical Product companies are likely to reflect a year-over-year decline. Let's see how SYK, COR, BAX, FMS and XRAY fare this time around.

Stryker (SYK) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Stryker's (SYK) third-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

Cencora (COR) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Cencora's (COR) fiscal fourth-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

BAX vs. SYK: Which Stock Is the Better Value Option?

by Zacks Equity Research

BAX vs. SYK: Which Stock Is the Better Value Option?

Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Santanu Roy headshot

NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day

by Santanu Roy

NeoGenomics and SolarEdge Technologies are part of the Zacks Bull and Bear of the Day article.

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

by Indrajit Bandyopadhyay

Here we pick three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye

by Zacks Equity Research

Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.

Andrew Rocco headshot

The 3 Widest Competitive Moats on Wall Street

by Andrew Rocco

Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.